Japanese encephalitis vaccine - Rhein Biotech

Drug Profile

Japanese encephalitis vaccine - Rhein Biotech

Latest Information Update: 13 Oct 2004

Price : $50

At a glance

  • Originator Rhein Biotech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Encephalitis virus infections

Most Recent Events

  • 13 Oct 2004 Discontinued - Preclinical for Encephalitis virus infections in Netherlands (unspecified route)
  • 31 Dec 2003 Crucell's PER.C6 technology is no longer licensed to Rhein Biotech
  • 31 Oct 2002 Rhein Biotech has been acquired by Berna Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top